Journal Browser Advanced Search Help
Journal Browser Advanced search HELP
J Korean Diabetes Assoc. 2006 Mar;30(2):96-103. Korean. Original Article.
Park JS , Lee YJ , Kim CS , Kim HJ , Park J , Ahn CW , Lee KY , Kim HJ , Won YJ , Ha HJ , Kwak HS , Cha BS , Lim SK , Kim KR , Lee HC .
Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Ewha Graduate School of Clinical Health Science, Seoul, Korea.
Department of Neurology, Yonsei University College of Medicine, Seoul, Korea.
Department of Internal Medicine, Kwandong University College of Medicine, Gangneung, Korea.

BACKGROUND: Atherosclerosis is one of the major causes of morbidity and mortality in patients with type 2 diabetes and pioglitazone has been reported to have antiatherogenic effect. The aim of this study was to investigate whether pioglitazone affects carotid intima-media thickness (IMT) and pulsatility index (PI) in type 2 diabetic patients. METHODS: A total of 40 type 2 diabetic patients were included and divided into two groups: the pioglitazone-treated group (pioglitazone 15 mg/day with gliclazide 80~320 mg/day for 12 weeks) (n = 20) and control group (gliclazide 80~320 mg/day for 12 weeks) (n = 20). The changes in lipid profile, insulin resistance, IMT, and PI were monitored to determine that pioglitazone improves cerebrovascular blood flow. RESULTS: The pioglitazone treatment significantly increased HDL-C, reduced triglyceride, insulin resistance and PI. IMT tended to decrease but the change was not significant. This study revealed that treatment with pioglitazone was associated with the improvement of cerebrovascular blood flow. CONCLUSIONS: Pioglitazone appears to be effective for the improvement of cerebrovascular blood flow in type 2 diabetic patients

Copyright © 2019. Korean Association of Medical Journal Editors.